Top videos
In this video a real case of the extremely rare disease "Fibrodysplasia ossificans progressiva" or what is called the "FOP" This disease is commonly misdiagnosed and usually end up by unnecessary surgery which exaggerate the disease. Children born with FOP characteristically have deformed great toes, possibly missing a joint or simply presenting with a notable lump at the minor joint. The first "flare-up" that leads to the formation of FOP bones usually occurs before the age of 10. FOP is a genetic disease. The bone growth progresses from the top downward, just as bones grow in fetuses. A child with FOP will typically develop bones starting at the neck, then on the shoulders, arms, chest area and finally on the feet. However it does not necessarily occur in this order due to injury-caused flare-ups. Often, the tumor-like lumps that characterize the disease appear suddenly. The gene that causes ossification is normally deactivated after a fetus' bones are formed in the womb, but in patients with FOP, the gene keeps working. Aberrant bone formation in patients with FOP occurs when injured connective tissue or muscle cells at the sites of injury or growth incorrectly express an enzyme for bone repair during apoptosis (self-regulated cell death), resulting in lymphocytes containing excess bone morphogenetic protein 4 (BMP4) provided during the immune system response. Since the incorrect enzyme remains unresolved within the immune response, the body continues providing the incorrect BMP4-containing lymphocytes. BMP4 is a product that contributes to the development of the skeleton in the normal embryo.
NOVEL METHOD: REAL ANATOMIC CUSTOM-MADE IMMEDIATE ZIRCONIA IMPLANT. YOUR DENTAL ROOT IS MILLED IN ZIRCONIA AND IN JUST 2 MINUTES SEATED, NO DRILLING, NO AUGMENTATION, NO MEMBRANES, FLAPLESS, NO 3D PLANNING, NO CAD/CAM SPLINTS OR GUIDED SURGERY REQUIRED! EASY AND CONSEQUENTIAL SYSTEM. NO MORE INCONGRUOUS AND UGLY SILVER-COLORED TITANIUM IMPLANTS IN TIME CONSUMING, PAINFUL AND COSTLY PROCEDURES. IT`S HIGH TIME TO RESPECT THE ANATOMY NOT ALTER IT BY DRILLING AND AUGMENTATION. BIOIMPLANT
The Fibroids Project Interviews Dr. Brown. Haywood Brown, MD, is the chair of the Department of Obstetrics and Gynecology at Duke University Medical Center. He also is a nationally recognized specialist in maternal-fetal medicine.
Inguinal hernia repair without mesh, Desarda Repair, no recurrence, pain, no mesh hernia surgery, hernia operation, no mesh, without mesh, hernia operation, hernia surgery, new method. http://www.desarda.com
Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a myeloproliferative disorder characterized by increased proliferation of the granulocytic cell line without the loss of their capacity to differentiate. Consequently, the peripheral blood cell profile shows an increased number of granulocytes and their immature precursors, including occasional blast cells.
CML is one of the few cancers known to be caused by a single, specific genetic mutation. More than 90% of cases result from a cytogenetic aberration known as the Philadelphia chromosome (see Pathophysiology).
CML progresses through 3 phases: chronic, accelerated, and blast. In the chronic phase of disease, mature cells proliferate; in the accelerated phase, additional cytogenetic abnormalities occur; in the blast phase, immature cells rapidly proliferate.[1] Approximately 85% of patients are diagnosed in the chronic phase and then progress to the accelerated and blast phases after 3-5 years. The diagnosis of CML is based on the histopathologic findings in the peripheral blood and the Philadelphia chromosome in bone marrow cells (see Workup).
CML accounts for 20% of all leukemias affecting adults. It typically affects middle-aged individuals. Uncommonly, the disease occurs in younger individuals. Younger patients may present with a more aggressive form of CML, such as in accelerated phase or blast crisis. Uncommonly, CML may appear as a disease of new onset in elderly individuals.
The goals of treatment are to achieve hematologic, cytogenetic, and molecular remission. Although a variety of medications have been used in CML, including myelosuppressive agents and interferon alfa, the tyrosine kinase inhibitor imatinib mesylate is currently the agent of choice, and other drugs in this category are playing increasingly important roles. However, allogeneic bone marrow transplantation is currently the only proven cure for CML.